Replimune, Inc. will lay off 63 employees from its Woburn facility this month. The company has filed a Worker Adjustment and Retraining Notification (WARN) notice, indicating plans for workforce reduction.
Replimune, Inc. Announces Layoffs in Woburn
Replimune, Inc. will lay off employees, according to the WARN notice filed on April 13, 2026. The notice indicates a significant impact on the workforce; however, the affected job positions have not been disclosed in detail.
The layoffs are expected to take effect from April 13 through April 24, 2026, at the Woburn, Massachusetts, facility. The layoffs follow a setback involving the company’s cancer treatment candidate RP1.
On April 10, Replimune announced that the FDA issued a Complete Response Letter for its Biologics License Application seeking approval of RP1 in combination with nivolumab for advanced melanoma.
Following the FDA’s decision, the company said it disagrees with the outcome. Replimune cited clinical data from its IGNYTE trial, which demonstrated a response rate of 34% and a median duration of 24.8 months, along with a positive safety profile.
The company also cited inconsistencies in the FDA’s review and communication process during the resubmission period, when a new review team was assigned.
Following the decision, Replimune announced that it is not feasible to continue developing RP1 without accelerated approval. Consequently, the company planned to downsize and scale back U.S.-based manufacturing operations.
Sushil Patel, CEO of Replimune, stated, “As we previously communicated, without timely accelerated approval, the development of RP1 will not be viable. We are devastated for our committed employees who have worked tirelessly for patients, but at this point, we have no choice but to eliminate jobs, including substantially scaling back our U.S.-based manufacturing operations. A treatment desperately needed by patients will not be available. Not because the medicine failed. Because the system did.”
About Replimune
Replimune is a clinical-stage biotechnology firm developing a novel category of cancer therapies. The company, based in Woburn, Massachusetts, was founded in 2015 and is focused on using the body’s immune system to better combat tumors.
Replimune is in the process of developing numerous investigational therapies in clinical trials. These therapies are undergoing trials as mono-therapies and in combination with existing immunotherapies.
The WARN notice is indicative of a transition in Replimune, Inc., as it deals with regulatory issues and evaluates its next steps. Additional information on the layoffs and employee support is not provided by the company in the current filing.
